NeuroDerm Announces Highly Positive Results from the Pivotal Phase III BouNDless Trial Evaluating ND0612 in Parkinson's Disease Patients with Motor Fluctuations
#Customers
Aug 28, 2019
www.prnewswire.com
Phase 3 Clinical Trial Evaluating Continuous Subcutaneous Carbidopa/Levodopa (ND0612) Initiated In The United States For Parkinson's Disease With Motor Fluctuations
#Customers
Jul 24, 2017
globenewswire.com
NeuroDerm Enters Definitive Agreement to be Acquired by Mitsubishi Tanabe Pharma Corporation for US$1.1 Billion in Cash
#Acquisition
Jun 13, 2017
www.globes.co.il
Neuroderm mulls several acquisition offers
#Acquisition
Mar 2, 2017
www.globes.co.il
Neuroderm jumps on successful trial results
#Customers
Jul 16, 2015
www.globes.co.il
NeuroDerm raises $67m in Nasdaq secondary offering
NeuroDerm Announces Highly Positive Results from the Pivotal Phase III BouNDless Trial Evaluating ND0612 in Parkinson's Disease Patients with Motor Fluctuations
#Customers
Aug 28, 2019
www.prnewswire.com
Phase 3 Clinical Trial Evaluating Continuous Subcutaneous Carbidopa/Levodopa (ND0612) Initiated In The United States For Parkinson's Disease With Motor Fluctuations
#Customers
Jul 24, 2017
globenewswire.com
NeuroDerm Enters Definitive Agreement to be Acquired by Mitsubishi Tanabe Pharma Corporation for US$1.1 Billion in Cash
#Acquisition
Jun 13, 2017
www.globes.co.il
Neuroderm mulls several acquisition offers
#Acquisition
Mar 2, 2017
www.globes.co.il
Neuroderm jumps on successful trial results
#Customers
Jul 16, 2015
www.globes.co.il
NeuroDerm raises $67m in Nasdaq secondary offering